

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 16, 2025

BALB/cAnN-Foxn1^{nu/nu}/Rj

RRID:IMSR_RJ:BALB-C-NUDE

Type: Organism

Proper Citation

RRID:IMSR_RJ:BALB-C-NUDE

Organism Information

URL: https://janvier-labs.com/en/fiche_produit/balb-c-nu_immunodeficient_mouse/

Proper Citation: RRID:IMSR_RJ:BALB-C-NUDE

Description: Mus musculus with name BALB/cAnN-Foxn1^{nu/nu}/Rj from IMSR.

Species: Mus musculus

Notes: gene symbol note: ; mutant strain:

Catalog Number: RJ:BALB-C-NUDE

Database: Janvier Labs

Database Abbreviation: RJ

Availability: embryo

Organism Name: BALB/cAnN-Foxn1^{nu/nu}/Rj

Record Creation Time: 20250513T061857+0000

Record Last Update: 20250513T072146+0000

Ratings and Alerts

No rating or validation information has been found for BALB/cAnN-Foxn1^{nu/nu}/Rj.

No alerts have been found for BALB/cAnN-Foxn1^{nu/nu}/Rj.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: Janvier Labs

Usage and Citation Metrics

We found 3387 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Ma Z, et al. (2025) AMDHD1 acts as a tumor suppressor and contributes to activation of TGF- β signaling pathway in cholangiocarcinoma. *Cell death and differentiation*, 32(1), 162.

Chi S, et al. (2025) BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair. *Translational oncology*, 51, 102212.

Li J, et al. (2025) Knockdown of CENPF induces cell cycle arrest and inhibits epithelial-mesenchymal transition progression in glioma. *Oncology letters*, 29(1), 61.

Jeong W, et al. (2025) Clinically Relevant and Precisely Printable Live Adipose Tissue-Based Bio-Ink for Volumetric Soft Tissue Reconstruction. *Advanced healthcare materials*, 14(1), e2402680.

Zou J, et al. (2025) MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14/LINC02159/FOXC2 axis. *Translational oncology*, 52, 102235.

Gao B, et al. (2025) Identification of cancer-associated fibroblast subtypes and distinctive role of MFAP5 in CT-detected extramural venous invasion in gastric cancer. *Translational oncology*, 51, 102188.

Wang X, et al. (2025) KLF14 inhibits tumor progression via FOSL1 in glioma. *Biochemistry and biophysics reports*, 41, 101885.

Fu W, et al. (2025) Copper-luteolin nanocomplexes for Mediating multifaceted regulation of oxidative stress, intestinal barrier, and gut microbiota in inflammatory bowel disease. *Bioactive materials*, 46, 118.

Jiang S, et al. (2025) Ubiquitin-specific protease 1 facilitates tumor immune escape from natural killer cells and predicts the prognosis in small cell lung cancer. *Oncology research*, 33(1), 213.

Hong S, et al. (2025) Revolutionizing drug delivery: low-intensity pulsed ultrasound (LIPUS)-driven deep penetration into hypoxic tumor microenvironments of cholangiocarcinoma. *Theranostics*, 15(1), 30.

Li T, et al. (2025) Kupffer Cell-derived IL6 Promotes Hepatocellular Carcinoma Metastasis Via the JAK1-ACAP4 Pathway. *International journal of biological sciences*, 21(1), 285.

Ren Z, et al. (2025) NCAPG promotes the malignant progression of endometrioid cancer through LEF1/SEMA7A/PI3K-AKT. *Journal of Cancer*, 16(2), 445.

Hu X, et al. (2025) The hybrid lipoplex induces cytoskeletal rearrangement via autophagy/RhoA signaling pathway for enhanced anticancer gene therapy. *Nature communications*, 16(1), 339.

Zhao S, et al. (2025) DCUN1D5 is a prognostic biomarker and correlated immune infiltrates and glycolysis in lung adenocarcinoma. *Scientific reports*, 15(1), 403.

Li X, et al. (2025) A new peptide inhibitor of C1QBP exhibits potent anti-tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair. *Clinical and translational medicine*, 15(1), e70162.

Lan D, et al. (2025) Abnormal upregulation of NUBP2 contributes to cancer progression in colorectal cancer. *Molecular and cellular biochemistry*, 480(1), 399.

Guo Y, et al. (2025) KRAS inhibitors may prevent colorectal cancer metachronous metastasis by suppressing TGF β mediated epithelial-mesenchymal transition. *Molecular medicine reports*, 31(1).

Cho YJ, et al. (2025) Repositioning of aripiprazole, an anti-psychotic drug, to sensitize the chemotherapy of pancreatic cancer. *International journal of molecular medicine*, 55(1).

Sun R, et al. (2025) Scaffolds functionalized with matrix metalloproteinase-responsive release of miRNA for synergistic magnetic hyperthermia and sensitizing chemotherapy of drug-tolerant breast cancer. *Bioactive materials*, 44, 205.

Huang J, et al. (2025) An injectable hyaluronic acid/lithium calcium silicate soft tissue filler with vascularization and collagen regeneration. *Bioactive materials*, 44, 256.